Keros Therapeutics, Inc.
KROSDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
KROS Earnings Report
EPS Est: $-1.25 | FQ end 2026-06
How KROS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dose A KER-012 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Keros Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Keros Therapeutics, Inc.'s (KROS) pipeline across Phase 2. Its lead program is Dose A KER-012 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Keros Therapeutics, Inc.'s next FDA catalyst?→
Keros Therapeutics, Inc.'s (KROS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KROS biotech catalysts?→
Add KROS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Keros Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.